000182657 001__ 182657
000182657 005__ 20240229145726.0
000182657 0247_ $$2doi$$a10.1080/1354750X.2022.2148745
000182657 0247_ $$2pmid$$apmid:36377411
000182657 0247_ $$2ISSN$$a1354-750X
000182657 0247_ $$2ISSN$$a1366-5804
000182657 0247_ $$2altmetric$$aaltmetric:138435110
000182657 037__ $$aDKFZ-2022-02829
000182657 041__ $$aEnglish
000182657 082__ $$a610
000182657 1001_ $$aLangnau, Carolin$$b0
000182657 245__ $$aRecovery of systemic hyperinflammation in patients with severe SARS-CoV-2 infection.
000182657 260__ $$aLondon$$bTaylor & Francis$$c2023
000182657 3367_ $$2DRIVER$$aarticle
000182657 3367_ $$2DataCite$$aOutput Types/Journal article
000182657 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674743212_18725
000182657 3367_ $$2BibTeX$$aARTICLE
000182657 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182657 3367_ $$00$$2EndNote$$aJournal Article
000182657 500__ $$a2023 Feb;28(1):97-110
000182657 520__ $$aIntroduction: Patients with cardiovascular disease (CVD) and acute SARS-CoV-2 infection might show an altered immune response during COVID-19. Material and methods: 23 patients with CVD and SARS-CoV-2 infection were prospectively enrolled and received a cardiological assessment at study entry and during follow-up visit. Inclusion criteria of our study were age older than 18 years, presence of CVD, and acute SARS-CoV-2 infection. The median age of the patient cohort was 69 (IQR 55-79) years. 12 (52.2%) patients were men. Peripheral monocytes and chemokine/cytokine profiles were analyzed. Results: Numbers of classical and non-classical monocytes were significantly decreased during acute SARS-CoV-2 infection compared to 3-month recovery. While classical monocytes reached the expected level in peripheral blood after 3 months, the number of non-classical monocytes remained significantly reduced. Discussion: All three monocyte subsets exhibited changes of established adhesion and activation markers. Interestingly, they also expressed higher levels of pro-inflammatory cytokines like macrophage migration inhibitory factor (MIF) at the time of recovery, although MIF was only slightly increased during the acute phase. Conclusion: Changes of monocyte phenotypes and increased MIF expression after 3-month recovery from acute SARS-CoV-2 infection may indicate persistent, possibly long-lasting, pro-inflammatory monocyte function in CVD patients.
000182657 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000182657 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182657 650_7 $$2Other$$aSARS-CoV-2 infection
000182657 650_7 $$2Other$$ahyperinflammation
000182657 650_7 $$2Other$$amonocytes
000182657 650_7 $$2Other$$aplatelets
000182657 650_7 $$2Other$$arecovery
000182657 7001_ $$aJaning, Henrik$$b1
000182657 7001_ $$aKocaman, Hüseyin$$b2
000182657 7001_ $$aGekeler, Sarah$$b3
000182657 7001_ $$0P:(DE-He78)b676990c2f64e3295740d42e356fb053$$aGünter, Manina$$b4$$udkfz
000182657 7001_ $$aPetersen, Álvaro$$b5
000182657 7001_ $$aJaeger, Philippa$$b6
000182657 7001_ $$aKoch, Barbara$$b7
000182657 7001_ $$aKreisselmeier, Klaus-Peter$$b8
000182657 7001_ $$aCastor, Tatsiana$$b9
000182657 7001_ $$aRath, Dominik$$b10
000182657 7001_ $$aGawaz, Meinrad$$b11
000182657 7001_ $$0P:(DE-He78)d3dbba28fe1239effd15962787cbc363$$aAutenrieth, Stella E$$b12$$udkfz
000182657 7001_ $$aMueller, Karin$$b13
000182657 773__ $$0PERI:(DE-600)1496523-9$$a10.1080/1354750X.2022.2148745$$gp. 1 - 19$$n1$$p97-110$$tBiomarkers$$v28$$x1354-750X$$y2023
000182657 909CO $$ooai:inrepo02.dkfz.de:182657$$pVDB
000182657 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b676990c2f64e3295740d42e356fb053$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000182657 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d3dbba28fe1239effd15962787cbc363$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000182657 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000182657 9141_ $$y2022
000182657 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000182657 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000182657 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000182657 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000182657 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMARKERS : 2022$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000182657 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000182657 9201_ $$0I:(DE-He78)F171-20160331$$kF171$$lDentritische Zellen bei Infektionen und Krebs$$x0
000182657 980__ $$ajournal
000182657 980__ $$aVDB
000182657 980__ $$aI:(DE-He78)F171-20160331
000182657 980__ $$aUNRESTRICTED